Diabetic foot attack is an acute manifestation of diabetic foot syndrome that requires rapid diagnosis and early initiation of complex therapy based on multidisciplinary team cooperation to save the affected limb. The term "attack" evokes the need for a rapid reaction as for "heart attack". Patients with diabetes mellitus and acute manifestations of diabetic foot syndrome have high risk for amputation of the lower limb, which is associated with higher morbidity and mortality. Complex therapy includes systemic antibiotic therapy, surgical debridement of ulceration, revascularization in the case of proven lower limb ischemia and an individualized offloading. Without the subsequent outpatient podiatric follow-up, the risk of recurrence increases significantly.
{"title":"Diabetic foot attack.","authors":"Milan Flekač","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Diabetic foot attack is an acute manifestation of diabetic foot syndrome that requires rapid diagnosis and early initiation of complex therapy based on multidisciplinary team cooperation to save the affected limb. The term \"attack\" evokes the need for a rapid reaction as for \"heart attack\". Patients with diabetes mellitus and acute manifestations of diabetic foot syndrome have high risk for amputation of the lower limb, which is associated with higher morbidity and mortality. Complex therapy includes systemic antibiotic therapy, surgical debridement of ulceration, revascularization in the case of proven lower limb ischemia and an individualized offloading. Without the subsequent outpatient podiatric follow-up, the risk of recurrence increases significantly.</p>","PeriodicalId":9645,"journal":{"name":"Casopis lekaru ceskych","volume":"163 5","pages":"194-196"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142615641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
From anthropometrics point of view, the Roma have retained a distinct individuality and thus differ from the majority population. They are also distinguished by cultural differences, which are reflected in the concept of health and health care consumption. The available data show socially and culturally determined health inequalities and disadvantages of the Roma compared to the majority population, which do not change in the long term. Among others, the low level of cultural competence and sensitivity of health professionals to the needs of minorities and specifically to the Roma ethnicity also plays a role. The article describes health-relevant cultural differences in the context of Roma culture and way of life of the Czech Roma and outlines some of the barriers faced by Roma in healthcare.
{"title":"Roma people in the Czech Republic and cultural differences in health and health care.","authors":"Helena Hnilicová","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>From anthropometrics point of view, the Roma have retained a distinct individuality and thus differ from the majority population. They are also distinguished by cultural differences, which are reflected in the concept of health and health care consumption. The available data show socially and culturally determined health inequalities and disadvantages of the Roma compared to the majority population, which do not change in the long term. Among others, the low level of cultural competence and sensitivity of health professionals to the needs of minorities and specifically to the Roma ethnicity also plays a role. The article describes health-relevant cultural differences in the context of Roma culture and way of life of the Czech Roma and outlines some of the barriers faced by Roma in healthcare.</p>","PeriodicalId":9645,"journal":{"name":"Casopis lekaru ceskych","volume":"163 5","pages":"203-208"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142615646","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The incidence of monoclonal gammopathy (MG) increases with age. In individuals over 80 years of age, we can diagnose the presence of monoclonal immunoglobulin (MIg) in up to 10 % of cases. Not only malignant diseases such as multiple myeloma (MM), but also benign forms such as MGUS (monoclonal gammopathy of undetermined significance) can lead to renal involvement. The light chains of immunoglobulins (LC) are the most damaging to the kidneys, as they are freely filtered into the urine due to their molecular weight. Detection of MIg relies mainly on a combination of immunofixation electrophoresis of serum (IELFO) and urine and determination of free light chains (FLC) of kappa and lambda and their ratio (κ/λ) in serum. The combination of these tests will detect the presence of MIg with 99 % sensitivity. Renal damage in MG may be caused by direct deposition of MIg in the glomeruli (e.g. AL amyloidosis, LC deposition disease) or tubules (in the distal tubule as a myeloma kidney or in the proximal tubule as Fanconi syndrome or proximal tubulopathy). Typical urinary findings in these diseases are moderate or severe proteinuria or nephrotic syndrome. Acute kidney injury (AKI) can be expected especially when serum FLC is >500 mg/l. Renal biopsy is crucial to establish an accurate diagnosis and thus initiate the correct treatment. Treatment of these types of renal damage involves the same treatment regimens used in the treatment of MM, including proteasome inhibitors or daratumumab.
单克隆丙种球蛋白病(MG)的发病率随着年龄的增长而增加。在 80 岁以上的人群中,我们可以诊断出单克隆免疫球蛋白(MIg)存在的比例高达 10%。不仅多发性骨髓瘤(MM)等恶性疾病,MGUS(意义未定的单克隆免疫球蛋白病)等良性疾病也会导致肾脏受累。免疫球蛋白(LC)的轻链对肾脏的损害最大,因为它们的分子量可以自由地滤入尿液。MIg的检测主要依靠血清(IELFO)和尿液的免疫固定电泳以及血清中卡帕和λ游离轻链(FLC)及其比值(κ/λ)的测定。结合这些检测方法可检测出是否存在 MG,灵敏度高达 99%。MG的肾损伤可能是由于MIg直接沉积在肾小球(如AL淀粉样变性、LC沉积病)或肾小管(在远端肾小管如骨髓瘤肾,或在近端肾小管如范可尼综合征或近端肾小管病变)。这些疾病的典型尿检结果是中度或重度蛋白尿或肾病综合征。特别是当血清FLC达到500毫克/升时,急性肾损伤(AKI)可能会出现。肾活检对于确定准确诊断并开始正确治疗至关重要。治疗这些类型的肾损伤需要采用与治疗 MM 相同的治疗方案,包括蛋白酶体抑制剂或达拉单抗。
{"title":"Renal impairment in monoclonal gammopathies and multiple myeloma.","authors":"Romana Ryšavá","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The incidence of monoclonal gammopathy (MG) increases with age. In individuals over 80 years of age, we can diagnose the presence of monoclonal immunoglobulin (MIg) in up to 10 % of cases. Not only malignant diseases such as multiple myeloma (MM), but also benign forms such as MGUS (monoclonal gammopathy of undetermined significance) can lead to renal involvement. The light chains of immunoglobulins (LC) are the most damaging to the kidneys, as they are freely filtered into the urine due to their molecular weight. Detection of MIg relies mainly on a combination of immunofixation electrophoresis of serum (IELFO) and urine and determination of free light chains (FLC) of kappa and lambda and their ratio (κ/λ) in serum. The combination of these tests will detect the presence of MIg with 99 % sensitivity. Renal damage in MG may be caused by direct deposition of MIg in the glomeruli (e.g. AL amyloidosis, LC deposition disease) or tubules (in the distal tubule as a myeloma kidney or in the proximal tubule as Fanconi syndrome or proximal tubulopathy). Typical urinary findings in these diseases are moderate or severe proteinuria or nephrotic syndrome. Acute kidney injury (AKI) can be expected especially when serum FLC is >500 mg/l. Renal biopsy is crucial to establish an accurate diagnosis and thus initiate the correct treatment. Treatment of these types of renal damage involves the same treatment regimens used in the treatment of MM, including proteasome inhibitors or daratumumab.</p>","PeriodicalId":9645,"journal":{"name":"Casopis lekaru ceskych","volume":"163 3","pages":"98-105"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141562767","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The aim of the article to present the development of artificial intelligence (AI) methods and their applications in medicine and health care. Current technological development contributes to generation of large volumes of data that cannot be evaluated only manually. We describe the process of patient care and its individual parts that can be supported by technology and data analysis methods. There are many successful applications that help in the decision support process, in processing complex multidimensional heterogeneous and/or long-term data. On the other side, failures appear in AI methods applications. In recent years, deep learning became very popular and to a certain extend it delivered promising results. However, it has certain flaws that might lead to misclassification. The correct methodological steps in design and implementation of selected methods to data processing are briefly presented.
{"title":"Artificial intelligence in medicine and healthcare: Opportunity and/or threat.","authors":"Lenka Lhotská","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The aim of the article to present the development of artificial intelligence (AI) methods and their applications in medicine and health care. Current technological development contributes to generation of large volumes of data that cannot be evaluated only manually. We describe the process of patient care and its individual parts that can be supported by technology and data analysis methods. There are many successful applications that help in the decision support process, in processing complex multidimensional heterogeneous and/or long-term data. On the other side, failures appear in AI methods applications. In recent years, deep learning became very popular and to a certain extend it delivered promising results. However, it has certain flaws that might lead to misclassification. The correct methodological steps in design and implementation of selected methods to data processing are briefly presented.</p>","PeriodicalId":9645,"journal":{"name":"Casopis lekaru ceskych","volume":"162 7-8","pages":"275-278"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141562754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
SARS-CoV-2 is a virus which infects the respiratory tract and may cause severe, occasionally life-threatening disease COVID-19. In more than 5% of symptomatic patients the infection is associated with post-acute symptoms. The initial contact of the virus with the immune system of the nasopharynx and oropharynx induces a mucosal immune response manifested by the production of secretory IgA (sIgA) antibodies which may contribute to the restriction of the infection to the upper respiratory tract and an asymptomatic or clinically mild disease. The current systemically administered vaccines protected against the severe COVID-19 infection and its post-acute sequelae. However, they do not induce antibodies in mucosal secretions in SARS-CoV-2-naive individuals. In contrast, in those who previously experienced mucosal infection, systemically administered vaccines may stimulate sIgA production. The clinical benefit of systemic vaccination convincingly documented in tens of millions of individuals overshadows the rare, sometimes controversial reports of complications encountered after vaccination. The inability of current SARS-CoV-2 vaccines to induce mucosal immune responses and to prevent the spreading of the virus by external secretions demonstrates the mutual independence of mucosal and systemic compartments of the immune system, and thus emphasizes need for the development of vaccines inducing protective immune responses in both compartments.
{"title":"COVID-19: to vaccinate or not to vaccinate - that is the question.","authors":"Jiří Městecký, Milan Raška","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>SARS-CoV-2 is a virus which infects the respiratory tract and may cause severe, occasionally life-threatening disease COVID-19. In more than 5% of symptomatic patients the infection is associated with post-acute symptoms. The initial contact of the virus with the immune system of the nasopharynx and oropharynx induces a mucosal immune response manifested by the production of secretory IgA (sIgA) antibodies which may contribute to the restriction of the infection to the upper respiratory tract and an asymptomatic or clinically mild disease. The current systemically administered vaccines protected against the severe COVID-19 infection and its post-acute sequelae. However, they do not induce antibodies in mucosal secretions in SARS-CoV-2-naive individuals. In contrast, in those who previously experienced mucosal infection, systemically administered vaccines may stimulate sIgA production. The clinical benefit of systemic vaccination convincingly documented in tens of millions of individuals overshadows the rare, sometimes controversial reports of complications encountered after vaccination. The inability of current SARS-CoV-2 vaccines to induce mucosal immune responses and to prevent the spreading of the virus by external secretions demonstrates the mutual independence of mucosal and systemic compartments of the immune system, and thus emphasizes need for the development of vaccines inducing protective immune responses in both compartments.</p>","PeriodicalId":9645,"journal":{"name":"Casopis lekaru ceskych","volume":"163 4","pages":"131-136"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142280712","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Both obesity and malnutrition in the elderly population are raising concerns. As majority of pharmacokinetic data are obtained from subjects with a healthy weight range in productive age, administration of correct dosing of drugs to obese elderly patients is quite challenging. All phases of the pharmacokinetics of drugs (absorption, distribution, metabolism and elimination) are potentially affected by the effect of aging but also by obesity or malnutrition. These changes are often potentiated in the case of a combination of obesity and older age. The problem is also that not all drugs are affected in the same way, therefore it is necessary to know the influence of age and obesity on the kinetics of the particular substance being assessed. 50% of seniors suffer from pain at home and up to 80% during hospitalization. In addition to general knowledge about the effect of age but also obesity and malnutrition on the kinetics of drugs, this overview presents the pharmacokinetic changes of analgesics caused by both obesity and malnutrition.
{"title":"Je obezita a malnutrice u geriatrických pacientů problémem z hlediska dávkování analgetik?","authors":"Eliška Dvořáčková","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Both obesity and malnutrition in the elderly population are raising concerns. As majority of pharmacokinetic data are obtained from subjects with a healthy weight range in productive age, administration of correct dosing of drugs to obese elderly patients is quite challenging. All phases of the pharmacokinetics of drugs (absorption, distribution, metabolism and elimination) are potentially affected by the effect of aging but also by obesity or malnutrition. These changes are often potentiated in the case of a combination of obesity and older age. The problem is also that not all drugs are affected in the same way, therefore it is necessary to know the influence of age and obesity on the kinetics of the particular substance being assessed. 50% of seniors suffer from pain at home and up to 80% during hospitalization. In addition to general knowledge about the effect of age but also obesity and malnutrition on the kinetics of drugs, this overview presents the pharmacokinetic changes of analgesics caused by both obesity and malnutrition.</p>","PeriodicalId":9645,"journal":{"name":"Casopis lekaru ceskych","volume":"163 1","pages":"32-37"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142709300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Polypharmacy is currently a serious problem that causes decrease in adherence and increased number of hospitalizations and mortality. WHO addresses polypharmacy in the Medication Without Harm campaign. Other initiatives that deal with polypharmacy are the International Group for Reducing Inappropriate Medication Use & Polypharmacy (IGRIMUP) and Choosing Wisely campaign. The correct approach to address polypharmacy consists of its prevention, i.e. not prescribing inappropriate or unnecessary medication and providing clear timeframe for medication that should not be continued life-long. Further on we should actively seek patients suffering from polypharmacy and intervene it by deprescription. Correctly provided deprescription can be done by means of various tools beginning from simple lists of inappropriate drugs (Beers criteria, STOPP/START) to more comprehensive approaches that evaluate the importance of each particular drug in patient's medication list and help to identify the least important ones that are candidates for deprescription (Medication Appropriateness Index, Good Palliative Geriatric Practice Algorithm and others). When evaluating the appropriateness of pharmacotherapy, we always check if the treatment aim is achieved, if the indication persists, appropriateness of dosing and if the patient understands the pharmacotherapeutical regimen. By this approach we try to eliminate the pharmacotherapy with very low or no benefit for particular patient. Clinical pharmacologist or pharmacist can significantly help with this time-consuming process.
{"title":"Polypragmazie a jak jí předcházet.","authors":"Jan Miroslav Hartinger, Daniel Laurus Bobek","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Polypharmacy is currently a serious problem that causes decrease in adherence and increased number of hospitalizations and mortality. WHO addresses polypharmacy in the Medication Without Harm campaign. Other initiatives that deal with polypharmacy are the International Group for Reducing Inappropriate Medication Use & Polypharmacy (IGRIMUP) and Choosing Wisely campaign. The correct approach to address polypharmacy consists of its prevention, i.e. not prescribing inappropriate or unnecessary medication and providing clear timeframe for medication that should not be continued life-long. Further on we should actively seek patients suffering from polypharmacy and intervene it by deprescription. Correctly provided deprescription can be done by means of various tools beginning from simple lists of inappropriate drugs (Beers criteria, STOPP/START) to more comprehensive approaches that evaluate the importance of each particular drug in patient's medication list and help to identify the least important ones that are candidates for deprescription (Medication Appropriateness Index, Good Palliative Geriatric Practice Algorithm and others). When evaluating the appropriateness of pharmacotherapy, we always check if the treatment aim is achieved, if the indication persists, appropriateness of dosing and if the patient understands the pharmacotherapeutical regimen. By this approach we try to eliminate the pharmacotherapy with very low or no benefit for particular patient. Clinical pharmacologist or pharmacist can significantly help with this time-consuming process.</p>","PeriodicalId":9645,"journal":{"name":"Casopis lekaru ceskych","volume":"163 1","pages":"3-8"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142709315","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The advent of large language models (LLMs) based on neural networks marks a significant shift in academic writing, particularly in medical sciences. These models, including OpenAI's GPT-4, Google's Bard, and Anthropic's Claude, enable more efficient text processing through transformer architecture and attention mechanisms. LLMs can generate coherent texts that are indistinguishable from human-written content. In medicine, they can contribute to the automation of literature reviews, data extraction, and hypothesis formulation. However, ethical concerns arise regarding the quality and integrity of scientific publications and the risk of generating misleading content. This article provides an overview of how LLMs are changing medical writing, the ethical dilemmas they bring, and the possibilities for detecting AI-generated text. It concludes with a focus on the potential future of LLMs in academic publishing and their impact on the medical community.
{"title":"Large language models are changing landscape of academic publications. A positive transformation?","authors":"Martin Májovský, Martin Černý, David Netuka","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The advent of large language models (LLMs) based on neural networks marks a significant shift in academic writing, particularly in medical sciences. These models, including OpenAI's GPT-4, Google's Bard, and Anthropic's Claude, enable more efficient text processing through transformer architecture and attention mechanisms. LLMs can generate coherent texts that are indistinguishable from human-written content. In medicine, they can contribute to the automation of literature reviews, data extraction, and hypothesis formulation. However, ethical concerns arise regarding the quality and integrity of scientific publications and the risk of generating misleading content. This article provides an overview of how LLMs are changing medical writing, the ethical dilemmas they bring, and the possibilities for detecting AI-generated text. It concludes with a focus on the potential future of LLMs in academic publishing and their impact on the medical community.</p>","PeriodicalId":9645,"journal":{"name":"Casopis lekaru ceskych","volume":"162 7-8","pages":"294-297"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141562758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Martin Černý, Daniel Kvak, Daniel Schwarz, Hynek Mírka, Jakub Dandár
In recent years healthcare is undergoing significant changes due to technological innovations, with Artificial Intelligence (AI) being a key trend. Particularly in radiodiagnostics, according to studies, AI has the potential to enhance accuracy and efficiency. We focus on AI's role in diagnosing pulmonary lesions, which could indicate lung cancer, based on chest X-rays. Despite lower sensitivity in comparison to other methods like chest CT, due to its routine use, X-rays often provide the first detection of lung lesions. We present our deep learning-based solution aimed at improving lung lesion detection, especially during early-stage of illness. We then share results from our previous studies validating this model in two different clinical settings: a general hospital with low prevalence findings and a specialized oncology center. Based on a quantitative comparison with the conclusions of radiologists of different levels of experience, our model achieves high sensitivity, but lower specificity than comparing radiologists. In the context of clinical requirements and AI-assisted diagnostics, the experience and clinical reasoning of the doctor play a crucial role, therefore we currently lean more towards models with higher sensitivity over specificity. Even unlikely suspicions are presented to the doctor. Based on these results, it can be expected that in the future artificial intelligence will play a key role in the field of radiology as a supporting tool for evaluating specialists. To achieve this, it is necessary to solve not only technical but also medical and regulatory aspects. It is crucial to have access to quality and reliable information not only about the benefits but also about the limitations of machine learning and AI in medicine.
近年来,由于技术创新,医疗保健领域正在发生重大变化,其中人工智能(AI)是一个重要趋势。特别是在放射诊断方面,根据研究,人工智能有可能提高诊断的准确性和效率。我们重点关注人工智能在根据胸部 X 光片诊断肺部病变(可能预示肺癌)方面的作用。尽管与胸部 CT 等其他方法相比,X 射线的灵敏度较低,但由于其常规用途,X 射线往往能在第一时间发现肺部病变。我们介绍了基于深度学习的解决方案,旨在改进肺部病变检测,尤其是在疾病的早期阶段。然后,我们分享了之前在两种不同临床环境中验证该模型的研究结果:一家发病率较低的综合医院和一家专业肿瘤中心。通过与不同经验水平的放射科医生的结论进行定量比较,我们的模型具有较高的灵敏度,但特异性低于放射科医生。在临床要求和人工智能辅助诊断的背景下,医生的经验和临床推理起着至关重要的作用,因此我们目前更倾向于灵敏度高于特异性的模型。即使是不可能的疑点,也要向医生提出。基于这些结果,我们可以预见,人工智能作为评估专家的辅助工具,未来将在放射学领域发挥重要作用。要实现这一目标,不仅要解决技术方面的问题,还要解决医疗和监管方面的问题。关键是要获得高质量的可靠信息,不仅要了解机器学习和人工智能在医学中的益处,还要了解其局限性。
{"title":"Artificial intelligence's contribution to early pulmonary lesion detection in chest X-rays: insights from two retrospective studies on a Czech population.","authors":"Martin Černý, Daniel Kvak, Daniel Schwarz, Hynek Mírka, Jakub Dandár","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>In recent years healthcare is undergoing significant changes due to technological innovations, with Artificial Intelligence (AI) being a key trend. Particularly in radiodiagnostics, according to studies, AI has the potential to enhance accuracy and efficiency. We focus on AI's role in diagnosing pulmonary lesions, which could indicate lung cancer, based on chest X-rays. Despite lower sensitivity in comparison to other methods like chest CT, due to its routine use, X-rays often provide the first detection of lung lesions. We present our deep learning-based solution aimed at improving lung lesion detection, especially during early-stage of illness. We then share results from our previous studies validating this model in two different clinical settings: a general hospital with low prevalence findings and a specialized oncology center. Based on a quantitative comparison with the conclusions of radiologists of different levels of experience, our model achieves high sensitivity, but lower specificity than comparing radiologists. In the context of clinical requirements and AI-assisted diagnostics, the experience and clinical reasoning of the doctor play a crucial role, therefore we currently lean more towards models with higher sensitivity over specificity. Even unlikely suspicions are presented to the doctor. Based on these results, it can be expected that in the future artificial intelligence will play a key role in the field of radiology as a supporting tool for evaluating specialists. To achieve this, it is necessary to solve not only technical but also medical and regulatory aspects. It is crucial to have access to quality and reliable information not only about the benefits but also about the limitations of machine learning and AI in medicine.</p>","PeriodicalId":9645,"journal":{"name":"Casopis lekaru ceskych","volume":"162 7-8","pages":"283-289"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141562755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Postoperative pneumonia is the most common complication in patients after lung resection for non-small cell lung cancer (NSCLC). The tolerable incidence of this complication ranges from 5 to 8 %. The aim of this study was to evaluate the influence of initial risk factors on the incidence of postoperative pneumonia in patients undergoing lung resection for NSCLC. A retrospective cohort study was conducted at the University Hospital Ostrava between January 1, 2016, and December 31, 2022. All adult patients who underwent pulmonary lobectomy for primary NSCLC during the study period were included in the study. A total of 350 patients were included in the study. The incidence of postoperative pneumonia was 10.9%. Analysis of baseline risk factors did not show a statistically significant association with the incidence of this complication. The only statistically significant finding was a longer hospital stay in patients with postoperative pneumonia. The risk of postoperative pneumonia in patients undergoing lung resection for non-small cell lung cancer cannot be clearly explained by the initial risk factors examined alone. The complex nature of this risk also requires a comprehensive approach to prevention, including both patient-centred measures and improved postoperative care.
{"title":"Risk factors for postoperative pneumonia in patients after lung resection for non-small cell lung cancer - results of a cohort study.","authors":"Markéta Kepičová, Lubomír Tulinský, Adéla Kondé, Čestmír Neoral, Lubomír Martínek","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Postoperative pneumonia is the most common complication in patients after lung resection for non-small cell lung cancer (NSCLC). The tolerable incidence of this complication ranges from 5 to 8 %. The aim of this study was to evaluate the influence of initial risk factors on the incidence of postoperative pneumonia in patients undergoing lung resection for NSCLC. A retrospective cohort study was conducted at the University Hospital Ostrava between January 1, 2016, and December 31, 2022. All adult patients who underwent pulmonary lobectomy for primary NSCLC during the study period were included in the study. A total of 350 patients were included in the study. The incidence of postoperative pneumonia was 10.9%. Analysis of baseline risk factors did not show a statistically significant association with the incidence of this complication. The only statistically significant finding was a longer hospital stay in patients with postoperative pneumonia. The risk of postoperative pneumonia in patients undergoing lung resection for non-small cell lung cancer cannot be clearly explained by the initial risk factors examined alone. The complex nature of this risk also requires a comprehensive approach to prevention, including both patient-centred measures and improved postoperative care.</p>","PeriodicalId":9645,"journal":{"name":"Casopis lekaru ceskych","volume":"163 3","pages":"94-97"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141562768","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}